Q1 FY 2027 saw 22% revenue growth, margin expansion, and strong cash flow, led by complex generics and peptide CDMO. Guidance remains positive for sustained growth and margins, with major launches and capacity ramp-ups planned.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.